Trametinib is an allosteric inhibitor of MEK and has been approved for treating metastatic melanoma and has been proposed as a therapeutic for FLC based on its effects on mouse cells expressing DNAJB1-PRKACA and overexpressing TGF-α (24). This evidence concerns the gene PRKACA and metastatic melanoma.